

GRAPETECH

NOVEMBER 2023

Doron Fuchs

+972547177713

Doronfuchs@grapetech-einav.com

ABOUT US

Grapetech, a company under foundation, Incorporated with Volcani Institute - Agricultural research Organization (ARO State of Israel, <https://www.agri.gov.il/en//pages/1023.aspx>) and by Doron Fuchs (Mendi Group Ltd).


Grapetech Mission is to transfer successful results of the research to production of two main products:

1. Obesity prevention and weight control
2. Anti- inflammatory treatment

All based on current research results



PROBLEM



OBESITY, PREVENTION

There are many ineffective diets, and already several prescribed drugs that partially help obese patients but no prevention available

ANTI-INFLAMMATORY

About 30% of the patients in need of anti-inflammatory drugs have no available remedy as it conflicts other medical needs


FINANCIALS

Anti-inflammatory drugs market evaluated 190B\$, Obesity drugs market is expected to be about 47B\$ by 2030.

USABILITY

Customers want something easy to use that helps make their life easier, and get immediate relief. The food supplementary OTC version will cater this imminent need

MARKET SIZE




OBESITY, PREVENTION

The expected anti-obesity market size is evaluated at 47B\$/Year by 2030

ANTI-INFLAMMATORY


Out of 190B\$ per year spending in this field our available market is about 30% - Ca. 57 B\$/Per year

Morgan Stanley Research expects the market for obesity drugs to reach \$54 billion by 2030.



2023-NOV

SOLUTION



CLOSE THE GAP

Obesity is officially considered as epidemical. Preventing obesity is sought by and highly invested.

TARGET AUDIENCE

Starting from young teens with obese tendency to adults and about 30% of the population that is in need of anti-inflammatory drugs

COST SAVINGS

Production using cost effective BIO-Reactors omitting need for agriculture seasoning and climate dependency.

EASY TO USE

First version of products as food supplementary and OTC.

PRODUCT OVERVIEW

UNIQUE

Obesity prevention is a fresh innovative approach and solving the anti-inflammatory requirement is essential for millions of patients

FIRST TO MARKET

Innovative Preventive solution for obesity for every age to avoid obesity and improve health for life

TESTED

Initial laboratory tests shown results and next phase to allow use (toxicity tests) and eventual FDA compound approval is planned

AUTHENTIC

The survey has been conducted by the Volcani Institute - Agricultural research Organization (ARO) an internationally reputed research institute.

OBESITY – An Epidemia we don't have to have

2023-NOV



PRODUCT OVERVIEW

TECHNICAL BACKGROUND

The development is based on bio-technology incorporating genetic engineering based on a unique black grape skin grown in bioreactors in controlled environment to produce the compound which resolves a remedy for Cytokine storm (inflammation) and as a by product found a means for stopping obesity and preventing wrong food consumption.

FUTURE USES

Further tests for use of the compound resulted in good reaction to liver diseases

Medical indications: Obesity treatment and restrain of inflammatory reactions including various conditions related to the Metabolic syndrome including Dyslipidemia, Diabetes, NASH, Autoimmune diseases, and Atherosclerosis.

2023-NOV



BUSINESS MODEL



RESEARCH

We based our numbers on Bloomberg, Globaldata healthcare, Morgan Stanley,



ABSTRACT

There are at least 8 major market players that may find our products as a compelling opportunity to their portfolio




DESIGN

We produce the base ingredients raw materials to cater the big market players do their own PLs

ANTI OBESITY DRUG MARKET

ANTI-OBESITY COMPANIES - POTENTIAL PARTNERS

- Alizyme
- Bayer AG
- Bristol-Myers Squibb
- Currax Pharmaceutical LLC
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- Norgine BV
- Norgine BV
- Novo Nordisk AS
- Pfizer Inc,
- Rhythm Pharmaceuticals
- Takeda Pharmaceuticals
- Vivus Inc.
- Zafgan
- Zydus Cadila



TWO PHASE INVESTMENT PLAN

PHASE 1 - 12-15 MONTHS

Investment of 350,000 USD

- Initial production line - Bio-reactors
- Toxicity tests for permit of food supplement
- Regulation of food supplement
- Protocols for testing on human subjects
- Additional budget available from state - 150,000 \$
- Legal and research continuation

PHASE 2 - 18-24 MONTHS

Investment of 2,000,000 USD

- FDA compound application 900,000- 1,000,000 \$
- Production facility for raw material 500,000 \$
- First PL contracts
- Continuation of R&D budgets participation of 100,000\$
- International roadshow 100,000\$
- Chief Scientist application for budget 50,000\$
- Participation in international marketing aid program

MEET THE TEAM




Doron Fuchs

Chairman & CEO

<https://www.linkedin.com/in/doron-fuchs/>



CTO



Dr. Miriam, Friedman Einat

Chief research Officer-Animal Science

<https://www.agri.gov.il/en/people/620.aspx>



Prof. Michal Oren Shamir

Chief Researcher - Agricultural Biotechnology

<https://www.agri.gov.il/en/people/575.aspx>



THANK YOU

Doron Fuchs

+972 547 177713

doronfuchs@grapetech-einav.com

2023-NOV